Loading company…
Suzhou Yilian Bio-Pharmaceutical develops antibody-drug conjugates for cancer treatment.
Founded in 2020 and based in China, Suzhou Yilian Bio-Pharmaceutical develops antibody-drug conjugates that deliver toxic drugs to cancer cells. In March 2021, it raised CNY 350 million from Xingze Capital, Qiming Venture Capital, and Loyal Valley Capital to develop its drug pipeline and research platform.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in